Antibody-drug conjugates (ADCs) have become one of the most important developments in modern precision oncology. By combining the targeting ability of an antibody with a highly potent therapeutic payload, ADCs are designed to deliver cancer-killing agents directly to cells expressing a specific molecular target.

But the next phase of ADC development is moving beyond ADC monotherapy. Researchers are increasingly investigating whether ADCs can work more effectively when combined with other treatments, including immune checkpoint inhibitors, targeted therapies, chemotherapy, endocrine therapy and other emerging anticancer approaches.

The rationale is straightforward: cancer is biologically complex, and attacking a tumor through multiple complementary mechanisms may produce deeper and more durable responses.

Recent research has strengthened interest in these strategies. A 2026 review in the Journal of Experimental Medicine describes ADCs as an increasingly important component of solid-tumor treatment, while highlighting combinations, next-generation designs and resistance-management strategies as major areas of development.

The central question is no longer simply whether ADCs can kill tumor cells. It is increasingly: What should an ADC be combined with to make cancer treatment more effective, durable and precise? For broader context on ADC and immunotherapy combinations, see The Challenges and Opportunities in Immunotherapy Research.

What Are Antibody-Drug Conjugates?

An antibody-drug conjugate is a targeted therapeutic consisting of three major components:

  • An antibody that recognizes a specific antigen on or around cancer cells.
  • A linker that connects the antibody to the therapeutic payload.
  • A cytotoxic payload designed to damage or kill the targeted cell.

After binding to its target, the ADC can be internalized by the cancer cell. The payload is then released and produces its intended anticancer effect.

Depending on the ADC, the payload may interfere with DNA, microtubules or topoisomerase activity.

This mechanism gives ADCs a unique position between conventional chemotherapy and targeted therapy: they use antibody-based targeting to deliver a potent cytotoxic agent.

However, target expression can vary between tumors and even between cells within the same tumor. Resistance can also develop through antigen loss, altered internalization, drug-efflux mechanisms and changes in payload sensitivity. These limitations are among the reasons combination therapy has become such an important research direction.

Why Combine ADCs With Other Cancer Therapies?

An ADC can be highly effective against susceptible cancer cells, but solid tumors rarely consist of a uniform population of identical cells. Tumors contain different cellular populations, signaling pathways and microenvironmental conditions.

Combination therapy attempts to exploit this complexity. For example, an ADC might directly kill antigen-positive tumor cells while an immune checkpoint inhibitor activates T cells against residual disease. Alternatively, a targeted therapy could block a survival pathway that cancer cells use to resist the ADC's payload.

The goal is not simply to give patients more drugs. The goal is to create mechanistic complementarity. A successful combination should ideally produce greater antitumor activity than either treatment could achieve alone without creating unacceptable overlapping toxicity.

Importantly, combination does not automatically mean synergy. Reviews of ADC combination therapy emphasize that combinations can produce additive effects, true synergy or, in some cases, increased toxicity without sufficient therapeutic benefit.

Medical Journal IMJ Health Call for Papers

Major ADC Combination Strategies in Solid Tumors

1. ADCs + Immune Checkpoint Inhibitors

One of the most promising combination strategies involves pairing ADCs with immune checkpoint inhibitors (ICIs).

Checkpoint inhibitors targeting pathways such as PD-1 or PD-L1 have transformed treatment for several cancers, but only a subset of patients achieve durable responses.

ADCs may potentially make tumors more immunologically visible. Some ADCs can induce forms of tumor-cell death associated with the release of danger signals and tumor antigens. These processes may encourage dendritic-cell activation and antigen presentation, potentially helping prime an immune response.

This creates a compelling biological rationale:

ADC → tumor-cell killing → antigen release → immune activation → checkpoint blockade → stronger T-cell response

Research published in Nature Reviews Cancer in 2025 highlighted immunogenic cell death, immune-cell activation and antibody-Fc interactions as important contributors to ADC activity beyond direct payload-mediated cytotoxicity.

This is why ADC-plus-immunotherapy combinations are receiving substantial attention in breast, lung and other solid tumors. For related insights on cancer immunotherapy, see What's Next in Cancer Treatment: Advances Beyond Immunotherapy.

Recent Clinical Developments

A Phase 1 trial (CTEP 10355) presented at AACR 2026 evaluated the combination of trastuzumab deruxtecan (T-DXd) with the PARP inhibitor olaparib in HER2-expressing solid tumors. The trial achieved a confirmed objective response rate of 46%, including one complete response and 12 partial responses, with a median progression-free survival of 15.2 months.

Beyond checkpoint inhibitors, researchers are exploring novel immune-modulating partners. Regeneron researchers demonstrated at the AACR Immuno-Oncology Conference that combining tumor-associated antigen-targeted CD28 agonistic antibodies with ADCs achieved complete tumor rejection and durable immune memory in tumors resistant to ADC monotherapy. This approach synergistically enhanced efficacy while enabling lower doses of cytotoxic drugs.

The PRaG3.0 Approach

A prospective, multi-center Phase 2 study (PRaG3.0) is investigating disitamab vedotin (RC48) combined with a PD-1 inhibitor, radiotherapy, and GM-CSF in advanced refractory HER2-expressing solid tumors. The protocol aims to leverage ADC-induced immunogenic cell death to amplify radioimmunotherapy effects, potentially establishing a new pan-cancer treatment paradigm.

2. ADCs + WEE1 Inhibitors: A New Frontier

One of the most significant recent developments in ADC combination research involves pairing ADCs with WEE1 inhibitors.

WEE1 kinase is a key regulator of the cell cycle, acting as a brake by phosphorylating and inhibiting CDK1 and CDK2. It plays a crucial role at the G1-S and G2-M checkpoints, ensuring proper DNA replication and repair before cell cycle progression. Inhibition of WEE1 disrupts these regulatory mechanisms, leading to stalled replication forks, DNA damage, and mitotic catastrophe, ultimately driving cancer cell death.

Since most ADCs exert anti-tumor activity by inducing DNA damage or mitotic defects, combining them with agents that exacerbate replication stress or disrupt DNA repair, such as WEE1 inhibitors, presents a rational strategy to enhance ADC efficacy.

Azenosertib and ADC Combinations

Research published in iScience in July 2026 evaluated the selective WEE1 inhibitor azenosertib in combination with ADCs carrying topoisomerase I inhibitor (TOP1i) or microtubule inhibitor (MTI) payloads.

Key findings include:

  • Azenosertib enhanced the activity of TOP1i-based ADCs, including trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan, increasing DNA damage and apoptosis.
  • The combination extended the duration of response while overcoming T-DXd resistance in patient-derived xenografts.
  • Synergistic effects were also observed with MTI-based ADCs, including mirvetuximab soravtansine, tisotumab vedotin, and enfortumab vedotin, associated with exacerbated mitotic defects and prolonged mitotic arrest.
  • All combinations enhanced efficacy and were well tolerated in vivo.

The research positions azenosertib as a broadly applicable enhancer of cytotoxic-payload ADCs, offering a promising strategy for patients with advanced solid tumors.

3. ADCs + Chemotherapy

Combining two cytotoxic strategies may appear counterintuitive because ADCs already deliver a potent anticancer payload. However, carefully selected chemotherapy combinations may have a role when the mechanisms of action are complementary.

For example, an ADC could target a specific tumor-cell population while conventional chemotherapy affects dividing cancer cells more broadly.

The challenge is finding a therapeutic window. Both treatments can produce overlapping adverse effects, including hematologic toxicity, gastrointestinal effects or other organ-specific complications depending on the drugs involved.

Consequently, modern research is moving toward rational rather than empiric combinations. The objective is to understand which tumors are most likely to benefit and how doses and schedules can be optimized.

4. ADCs + PARP Inhibitors: Overcoming Tolerability Challenges

PARP inhibitors block cancer cells' ability to repair DNA damage, making them synergistic partners for Top1 inhibitor-based ADCs. However, overlapping toxicity to healthy cells, particularly in the bone marrow, has limited this combination.

The CTEP 10355 trial optimized intermittent olaparib dosing to address this issue. Administering olaparib on days 8 through 14 of the treatment cycle proved highly tolerable, with a 12% rate of grade 3 neutropenia compared to 30% in the continuous dosing group.

This illustrates how schedule optimization can unlock the therapeutic potential of rational ADC combinations.

5. ADCs + Targeted Therapies

Another important strategy is combining an ADC with a molecularly targeted therapy. Targeted drugs can inhibit signaling pathways that help cancer cells survive, proliferate or repair treatment-induced damage.

This can theoretically make tumor cells more vulnerable to the ADC payload. For example, if a cancer relies on a particular signaling pathway to survive cellular stress, inhibiting that pathway while delivering an ADC payload could create a stronger antitumor effect.

Research reviews increasingly identify targeted agents as one of the major categories being investigated alongside ADCs. This approach could become particularly important as researchers learn more about biomarkers of ADC resistance.

The Rise of Next-Generation ADCs

Combination therapy is only one part of the ADC revolution. Researchers are simultaneously redesigning the ADC itself.

A 2026 perspective in Acta Pharmacologica Sinica notes that more than 20 ADCs had been approved and more than 300 candidates were in clinical development globally, while highlighting persistent challenges involving antigen heterogeneity, internalization, payload resistance and treatment-related toxicity.

Next-generation strategies include:

  • Improved antibody engineering
  • More selective linkers
  • Novel payloads
  • Higher or controlled drug-to-antibody ratios
  • Bispecific ADCs
  • Dual-payload approaches
  • Tumor-microenvironment-responsive drug release
  • Conditional or masked ADCs
  • Improved tumor penetration

These technologies could make combination strategies even more sophisticated. Instead of simply combining an existing ADC with another drug, researchers may eventually design the ADC itself to deliver multiple complementary functions.

Bispecific and Dual-Payload ADCs: A New Direction

Dual-Payload ADCs

One major development is the concept of dual-payload ADCs. Traditional ADCs generally deliver one primary cytotoxic payload. Dual-payload approaches attempt to deliver two different therapeutic mechanisms through a single targeted construct.

The theoretical advantage is similar to combination therapy: Two mechanisms of tumor killing + one targeting system. This could potentially reduce the likelihood of resistance caused by changes in sensitivity to one particular payload.

DR319-DP: A Bispecific Bipayload ADC

At AACR 2026, Doer Bio presented preclinical data for DR319-DP, a first-in-class Nectin-4/Trop-2 bispecific bipayload ADC.

The drug combines a "1+1" bispecific antibody architecture with a dual-payload conjugation platform, incorporating a topoisomerase I inhibitor (DAR 4) and a microtubule inhibitor (MMAE, DAR 2).

Key preclinical findings include:

  • The antibody design features an avidity-driven anti-Trop-2 VHH (low affinity/high avidity) and an anti-Nectin-4 monoclonal antibody, enhancing binding to double-positive tumor cells while reducing on-target/off-tumor binding to single-positive cells.
  • DR319-DP demonstrated superior bystander killing activity compared to benchmark ADCs.
  • At 1 mg/kg, DR319-DP achieved tumor inhibition comparable to PADCEV at 8 mg/kg and the combination of PADCEV + SKB264.
  • A single administration led to significant regression of large established tumors in a triple-negative breast cancer PDX model.

The preclinical data suggest DR319-DP may comprehensively outperform traditional single-target or single-payload ADCs in terms of precision, efficacy, safety, and potential to overcome resistance.

Overcoming ADC Resistance: A Major Research Focus

Even successful ADCs can eventually stop working.

Several resistance mechanisms have been proposed or observed, including:

  • Antigen loss – Cancer cells may reduce or eliminate expression of the antigen targeted by the ADC.
  • Reduced internalization – The ADC may bind to the tumor cell but fail to enter the cell efficiently.
  • Payload resistance – Cancer cells may become less sensitive to the payload.
  • Drug efflux – Some tumor cells can increase mechanisms that remove cytotoxic compounds from the cell. The efflux pump system, primarily comprising P-glycoprotein, multidrug resistance-associated proteins, and breast cancer resistance protein, actively exports cytotoxic agents out of tumor cells, diminishing intracellular drug accumulation and attenuating ADC efficacy.
  • Tumor heterogeneity – Not every cancer cell may express the target at a sufficient level.
  • Changes in the tumor microenvironment – Immune suppression and physical barriers within solid tumors can limit drug activity.

These mechanisms explain why researchers increasingly view combination therapy as a strategy for preventing or overcoming resistance, rather than simply increasing drug potency.

Strategies to Overcome Resistance

Several approaches are being explored to counteract P-gp-mediated resistance:

  • Rational payload engineering – Developing cytotoxic compounds that evade P-gp recognition. Exatecan, a topoisomerase I inhibitor, is not a preferred substrate for P-gp and has been incorporated into ADCs like OBI-992, which retained efficacy in P-gp-overexpressing cells.
  • Pharmacological inhibition of P-gp – Using third-generation inhibitors such as tariquidar, zosuquidar, and laniquidar, which have shown potential to restore drug sensitivity in preclinical models.

A 2025 review in the Journal of Hematology & Oncology emphasizes that emerging strategies now emphasize precision targeting through bispecific ADCs, alongside advancements in linker chemistry, payload design, and TME modulation, with rational combination therapies emerging as a promising approach to reverse ADC resistance.

The Importance of Biomarkers

The future of ADC combinations will depend heavily on patient selection. Giving every patient the same combination may expose some people to unnecessary toxicity without providing additional benefit.

Researchers are therefore searching for biomarkers that can predict:

  • Target expression
  • ADC internalization
  • Payload sensitivity
  • Immune responsiveness
  • Risk of resistance
  • Likelihood of treatment-related toxicity

This could eventually allow oncologists to select a combination based on the molecular characteristics of an individual tumor. That is where ADC research intersects directly with precision oncology. For insights into AI's role in biomarker discovery, see The Role of Artificial Intelligence in Medical Research.

Safety: The Biggest Challenge in Combination Therapy

More treatment does not necessarily mean better treatment. ADCs can cause significant adverse effects depending on their target, payload and molecular design. When another anticancer drug is added, toxicity can increase.

Potential concerns include:

  • Bone-marrow suppression
  • Liver toxicity
  • Gastrointestinal toxicity
  • Peripheral neuropathy
  • Interstitial lung disease or pneumonitis with certain ADCs
  • Ocular toxicity with some ADC platforms
  • Cardiac effects with selected therapies

This makes dose optimization essential. Recent pharmacology research emphasizes that exposure-to-efficacy and exposure-to-safety relationships can vary substantially among ADCs, suggesting that pharmacokinetic-guided dosing may help optimize the balance between efficacy and toxicity.

What Does the Latest Research Tell Us?

The current evidence points toward several important conclusions. First, ADC monotherapy remains an important foundation, but combination therapy is becoming increasingly central to the field. Second, the strongest combinations are likely to be those supported by a clear biological mechanism rather than simply combining multiple active drugs. Third, immunotherapy is one of the most compelling partners for ADCs because some ADCs can influence the immune environment in addition to directly killing tumor cells. Fourth, next-generation ADC engineering may eventually blur the distinction between a single drug and a combination therapy by incorporating multiple payloads or targeting mechanisms into one platform. Finally, biomarker-driven treatment selection will likely determine which patients benefit most.

What Could the Future of ADC Combination Therapy Look Like?

The future may move from relatively simple combinations toward multi-layered precision treatment.

A potential future treatment model could involve:

Tumor sequencing → biomarker identification → target selection → personalized ADC → immune checkpoint therapy → resistance monitoring → treatment adaptation

Artificial intelligence and computational biology could further improve this process by helping researchers identify tumor targets, predict resistance and match patients to the most appropriate combinations.

The field is also moving toward earlier-stage treatment, where eliminating microscopic residual disease may be easier than treating widespread metastatic disease. This could significantly expand the role of ADCs in oncology.

ADC combination strategies represent one of the most dynamic areas of modern solid-tumor oncology. The first generation of ADCs established that antibodies can deliver highly potent cytotoxic payloads to selected cancer cells. The next generation is asking a more ambitious question: Can ADCs be combined with other biological mechanisms to produce deeper, longer-lasting tumor control?

The answer may increasingly depend on rational combinations involving immune checkpoint inhibitors, targeted therapies, chemotherapy, WEE1 inhibitors and emerging immune-modulating approaches.

Recent research has strengthened the evidence base. The WEE1 inhibitor azenosertib has demonstrated broad synergy with both TOP1i- and MTI-based ADCs in preclinical models. Bispecific bipayload ADCs like DR319-DP are showing breakthrough potential in overcoming efficacy and resistance challenges. Clinical trials are optimizing dosing schedules for PARP inhibitor-ADC combinations, achieving promising response rates with improved tolerability. And novel immune-activating approaches are demonstrating the ability to achieve complete tumor rejection in ADC-resistant tumors.

At the same time, next-generation ADC engineering—including bispecific targeting, novel payloads and dual-payload platforms—is expanding the possibilities of targeted cancer treatment. Research emphasizes that overcoming antigen heterogeneity, resistance and toxicity will be critical to realizing the full potential of these therapies.

The most important shift is therefore not simply from chemotherapy to ADCs. It is from single-mechanism treatment toward intelligently designed therapeutic combinations. As clinical trials mature and biomarker science improves, ADC combinations could become an increasingly important component of precision oncology—particularly for patients with advanced solid tumors that have limited treatment options.

The future of ADC therapy may ultimately be defined not by one drug, but by how intelligently that drug is combined with the rest of the cancer-treatment arsenal. For those considering doctoral research in this area, Top 10 Pharmaceutical Research Topics for PhD offers guidance on selecting impactful research directions.

Continue Exploring Our Blog